...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy
【24h】

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy

机译：对干扰素-β治疗反应欠佳的多发性硬化症患者的治疗选择

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose: Although the first-line disease-modifying therapies (DMTs) interferon beta and glatiramer acetate have a favourable benefit-to-risk profile, they are only partially effective for treating relapsing-remitting multiple sclerosis (RRMS). The optimization of treatment in patients who do not show a maximum response to first-line therapy is critical for achieving the best long-term outcomes. Treatment strategies for patients with a suboptimal response include switching to another first-line DMT or a second-line DMT. Natalizumab and fingolimod are approved for RRMS with high disease activity in the European Union and Canada. Methods: A comprehensive literature search for articles published between 1990 and April 2012 was undertaken. Results: This review discusses key clinical and safety data for fingolimod and natalizumab, particularly in the patient subgroups for whom these treatments are approved. Benefit-to-risk profiles, including first-dose cardiovascular effects associated with fingolimod and the risk of progressive multifocal encephalopathy with natalizumab, are discussed. Conclusion: A descriptive comparison of fingolimod and natalizumab is provided in the context of the decision-making process of how and when to switch patients who have a suboptimal response to first-line therapy.
机译：背景和目的：尽管一线疾病改良疗法（DMT）干扰素β和醋酸格拉替雷具有有利的获益风险特征，但它们仅部分治疗复发缓解型多发性硬化症（RRMS）。对于一线治疗未显示出最大反应的患者，最佳治疗方案对于获得最佳长期疗效至关重要。对于次优反应患者的治疗策略包括改用另一种一线DMT或二线DMT。纳他珠单抗和芬戈莫德已获欧盟和加拿大批准用于具有高疾病活性的RRMS。方法：对1990年至2012年4月之间发表的文章进行了全面的文献检索。结果：这篇综述讨论了芬戈莫德和那他珠单抗的关键临床和安全性数据，特别是在这些治疗被批准的患者亚组中。讨论了风险至风险的概况，包括与芬戈莫德相关的首剂心血管效应以及那他珠单抗进行性多灶性脑病的风险。结论：芬戈莫德和那他珠单抗的描述性比较是在如何以及何时更换对一线治疗反应不佳的患者的决策过程中提供的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号